Shire Orphan Therapies GmbH / Bayer Pharma AG / Mediwound Germany Gmbh / uniQure biopharma B.V. / Eisai Ltd / ViroPharma / Genzyme Europe B.V. / Development Centre (Europe) Ltd / Swedish Orphan Biovitrum International AB / Raptor Pharmaceuticals Europe B.V. / Gilead Sciences International Limited / Amgen Europe B.V. / Medac GmbH / Farmaceutici SpA / Meda AB / Novartis Europharm Ltd / Glaxo Group Ltd / Pharmaxis Pharmaceuticals Limited / Lipomed GmbH / Orphan Europe S.a.r.l. / ARIAD Pharma Ltd / Eaton / Shire Human Genetic Therapies AB / Janssen-Cilag International NV / Biomarin Europe Ltd / SpePharm Holding B.V. / Merck Serono Europe Ltd / InterMune UK Ltd. / Vertex Pharmaceuticals (U.K.) Limited / Celgene Europe Limited / Pfizer Ltd / / /
Event
Man-Made Disaster / /
Facility
Genzyme Europe B.V. NAGLAZYME N-acetylgalactosamine-4sulfatase INN / Takeda Global Research and Development Centre / /
IndustryTerm
treatment of growth failure / medicinal products / treatment of Lambert-Eaton myasthenic syndrome / treatment of patients with Hunter syndrome / treatment of seizures associated with Lennox Gastaut syndrome / Treatment of adult patients with Short Bowel Syndrome / treatment of cystic fibrosis / /